[1] Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, et al. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol, 2009, 15: 280-288.
[2] Garcia-Compean D, Jaquez-Quintana JO, Lavalle-Gonzalez FJ, et al. The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis. A prospective study. Ann Hepatol, 2012, 11: 240-248.
[3] Garcia-Compean D, Gonzalez-Gonzalez JA, Lavalle-Gonzalez FJ, et al. The treatment of diabetes mellitus of patients with chronic liver disease. Ann Hepatol, 2015, 14: 780-788.
[4] Beitelshees AL, Leslie BR, Taylor SI. Sodium-Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research. Diabetes, 2019, 68: 1109-1120.
[5] Saffo S, Taddei T. SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites. Clin Liver Dis, 2018, 11: 141-144.
[6] Lee W, Wells C, McCall J, et al. Prevalence of diabetes in liver cirrhosis: A systematic review and meta-analysis. Diabetes Metab Res Rev, 2019, 35: e3157.
[7] Huang Y, Wang T, Lin S, et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: a nationwide cohort study. Clin Infect Dis, 2013, 57: 1695-1702.
[8] Elkrief L, Chouinard P, Bendersky N, et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology,2014, 60: 823-831.
[9] Quintana J, García-Compean D, González J, et al. The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study. Ann Hepatol, 2011, 10: 56-62.
[10] Holstein A, Hinze S, Thiessen E, et al. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol, 2002, 17: 677-681.
[11] Nishida T, Tsuji S, Tsujii M, et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol, 2006, 101: 70-75.
[12] García-Compeán D, Jáquez-Quintana J, Lavalle-González F, et al. Subclinical abnormal glucose tolerance is a predictor of death in liver cirrhosis. World J Gastroenterol, 2014, 20: 7011-7018.
[13] Crespo J, Cayón A, Fernández-Gil P, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology,2001, 34: 1158-1163.
[14] Marra F, Bertolani CJH. Adipokines in liver diseases. Hepatology,2009, 50: 957-969.
[15] Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology, 2008, 15: 91-101.
[16] Anty R, Lemoine M. Liver fibrogenesis and metabolic factors. Clin Res Hepatol Gastroenterol, 2011, 35 Suppl 1: S10-20.
[17] Garcia-Compean D, Jaquez-Quintana JO, Lavalle-Gonzalez FJ, et al. Plasma cytokine levels imbalance in cirrhotic patients with impaired glucose tolerance and diabetes mellitus. A prospective study. Ann Hepatol, 2014, 13: 403-410.
[18] Zhang X, Harmsen WS, Mettler TA, et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology, 2014, 60: 2008-2016.
[19] Malaguarnera R, Belfiore A. The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells. Front Endocrinol, 2014, 5: 10.
[20] Gines P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology, 1987, 93: 234-241.
[21] Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med, 2015, 66: 255-270.
[22] Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J, 2016, 37: 1526-1534.
[23] Montalvo-Gordon I, Chi-Cervera LA, Garcia-Tsao G. Sodium-Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes. Hepatology, 2020, 72: 1880-1882.
[24] 江滔, 钱筱雨. SGLT_2抑制剂治疗糖尿病伴肝硬化失代偿期1例体会. 糖尿病新世界, 2020, 23: 55-57.
[25] Storgaard H, Gluud L, Bennett C, et al. Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS One,2016, 11: e0166125.
[26] Bonora BM, Avogaro A, Fadini GP, et al. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature. Diabetes Obes Metab,2018, 20: 25-33. |
